Authors:
Ascioglu, S
De Pauw, BE
Donnelly, JP
Collette, L
Citation: S. Ascioglu et al., Reliability of clinical research on invasive fungal infections: a systematic review of the literature, MED MYCOL, 39(1), 2001, pp. 35-40
Authors:
de Wit, R
Roberts, JT
Wilkinson, PM
de Mulder, PHM
Mead, GM
Fossa, SD
Cook, P
de Prijck, L
Stenning, S
Collette, L
Citation: R. De Wit et al., Equivalence of three or four cycles of bleomycin, etoposide, and cisplatinchemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European organization for research and treatment of cancer genitourinary tract cancer cooperative group and the medicalresearch council, J CL ONCOL, 19(6), 2001, pp. 1629-1640
Authors:
Sternberg, CN
de Mulder, PHM
Schornagel, JH
Theodore, C
Fossa, SD
van Oosterom, AT
Witjes, F
Spina, M
van Groeningen, CJ
de Balincourt, C
Collette, L
Citation: Cn. Sternberg et al., Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy amd recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European organization for research and treatment of cancerprotocol no. 30924, J CL ONCOL, 19(10), 2001, pp. 2638-2646
Authors:
Fossa, SD
Slee, PHT
Brausi, M
Horenblas, S
Hall, RR
Hetherington, JW
Aaronson, N
de Prijck, L
Collette, L
Citation: Sd. Fossa et al., Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: A phase III study of the European Organization for Research and Treatment of Cancer Genitourinary Group, J CL ONCOL, 19(1), 2001, pp. 62-71
Authors:
Lavagnini, P
Cartei, F
Princivalle, S
Bolla, M
Collette, L
Zurlo, A
de Reijke, T
Ash, D
Batterman, J
Blank, L
Citation: P. Lavagnini et al., Development of a joint (ESTRO-EAU-EORTC) survey of early prostate cancer treatment status update, TUMORI, 87(4), 2001, pp. S135-S135
Citation: L. Collette et al., Why phase III trials of maximal androgen blockade versus castration in M-1prostate cancer rarely show statistically significant differences, PROSTATE, 48(1), 2001, pp. 29-39
Authors:
De Mulder, PHM
Theodore, C
Sella, A
Koriakine, O
Sternberg, CN
Collette, L
de Balincourt, C
Citation: Phm. De Mulder et al., Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-alpha as second-line treatment of advanced transitional cell cancer of the urothelial tract, ANN ONCOL, 11(11), 2000, pp. 1391-1394
Authors:
Vrieling, C
Collette, L
Fourquet, A
Hoogenraad, WJ
Horiot, JC
Jager, JJ
Pierart, M
Poortmans, PM
Struikmans, H
Maat, B
Van Limbergen, E
Bartelink, H
Citation: C. Vrieling et al., The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial, RADIOTH ONC, 55(3), 2000, pp. 219-232
Authors:
Van Der Meijden, A
Sylvester, R
Collette, L
Bono, A
Ten Kate, F
Citation: A. Van Der Meijden et al., The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: A combined analysis of 5 European organization for research and treatment of cancer trials, J UROL, 164(5), 2000, pp. 1533-1537
Authors:
Duchateau, L
Collette, L
Sylvester, R
Pignon, JP
Citation: L. Duchateau et al., Estimating number of events from the Kaplan-Meier curve for incorporation in a literature-based meta-analysis: What you don't see you can't get!, BIOMETRICS, 56(3), 2000, pp. 886-892
Authors:
Collette, L
Sylvester, RJ
Stenning, SP
Fossa, SD
Mead, GM
de Wit, R
de Mulder, PHM
Neymark, N
Lallemand, E
Kaye, SB
Citation: L. Collette et al., Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma, J NAT CANC, 91(10), 1999, pp. 839-846
Authors:
Viscoli, C
Girmenia, C
Marinus, A
Collette, L
Martino, P
Vandercam, B
Doyen, C
Lebeau, B
Spence, D
Krcmery, V
De Pauw, B
Meunier, F
Citation: C. Viscoli et al., Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC), CLIN INF D, 28(5), 1999, pp. 1071-1079
Authors:
Vrieling, C
Collette, L
Bartelink, E
Borger, JH
Brenninkmeyer, SJ
Horiot, JC
Pierart, M
Poortmans, PM
Struikmans, H
Van der Schueren, E
Van Dongen, JA
Van Limbergen, E
Bartelink, H
Citation: C. Vrieling et al., Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC "boost versus no boost" trial, INT J RAD O, 45(3), 1999, pp. 667-676
Authors:
Vrieling, C
Collette, L
Fourquet, A
Hoogenraad, WJ
Horiot, JC
Jager, JJ
Pierart, M
Poortmans, PM
Struikmans, H
Van der Hulst, M
Van der Schueren, E
Bartelink, H
Citation: C. Vrieling et al., The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" trial, INT J RAD O, 45(3), 1999, pp. 677-685
Citation: R. Sylvester et L. Collette, Statistical considerations of chemoprevention clinical trials in prostate cancer, EUR UROL, 35(5-6), 1999, pp. 519-522
Authors:
Ellis, M
Spence, D
de Pauw, B
Meunier, F
Marinus, A
Collette, L
Sylvester, R
Meis, J
Boogaerts, M
Selleslag, D
Kremery, V
von Sinner, W
MacDonald, P
Doyen, C
Vandercam, B
Citation: M. Ellis et al., An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis, CLIN INF D, 27(6), 1998, pp. 1406-1412